Zealand Pharma A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZEAL.CO research report →
About the company
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia.
- CEO
- Adam Sinding Steensberg
- IPO
- 2010
- Employees
- 385
- HQ
- Copenhagen, DK
Price Chart
- Market Cap
- $19.97B
- P/E
- 3.12
- P/S
- 2.16
- P/B
- 1.38
- EV/EBITDA
- 2.45
- Div Yield
- 0.00%
- Gross Margin
- 99.72%
- Op Margin
- 73.88%
- Net Margin
- 69.22%
- ROE
- 42.59%
- ROIC
- 42.14%
- Revenue
- $9.21B · 14598.86%
- Net Income
- $6.46B · 698.34%
- EPS
- $91.56 · 663.79%
- Op Income
- $7.16B
- FCF YoY
- 788.43%
- 52W High
- $556.00
- 52W Low
- $233.50
- 50D MA
- $306.26
- 200D MA
- $395.96
- Beta
- 0.59
- Avg Volume
- 480.40K
Get TickerSpark's AI analysis on ZEAL.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ZEAL.CO coverage
Recent articles, reports, and earnings notes.
No research on ZEAL.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZEAL.CO report →Similar companies
Peers in the same neighborhood.